Data / Drug companies / Mycophenolate mofetil

Mycophenolate mofetil: 37 companies and 61 products in the FDA NDC directory

Mycophenolate mofetil is listed in the FDA National Drug Code Directory by 37 companies, with 61 products in commercial distribution. 57 of the products (93.4%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; tablet, film coated; powder, for suspension, and the newest product started marketing on October 15, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies listing it

37

Products

61

Generic (ANDA) products

57 (93.4%)

Application numbers

32

Routes

Oral, Intravenous

Brand names

CellCept, Myhibbin

openFDA record search

api.fda.gov

Companies that list mycophenolate mofetil

Ranked by number of products. Finished drugs in commercial distribution.

Dosage forms

Marketing categories

Pharmacologic classes

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.